Mucocort AB has received a patent in the United States for its innovative mucoadhesive patch technology, M045A, developed for the treatment of recurrent aphthous stomatitis (mouth ulcers). The approval marks a major milestone for the company and represents an important validation of its proprietary technology platform.
Mucocort AB today announced that the company has received a notice of approval for a Swedish patent covering the antimicrobial mechanism of action in its innovative treatment patch, M045A, developed for the treatment of oral ulcers caused by aphthae (Recurrent Aphthous Stomatitis).
The innovative patch M045A, developed by Mucocort for the treatment of Recurrent Aphthous Stomatitis (commonly known as canker sores), has reached an important milestone with the filing of a new patent application. This latest application focuses specifically on the patch’s unique antimicrobial effect, further strengthening the technology’s intellectual property portfolio.
Just weeks after being granted a patent in Australia, Mucocort AB has achieved yet another significant milestone — this time in Japan. The newly approved patent for its innovative mucoadhesive patch, M045A, designed for the treatment of oral aphthous ulcers, further strengthens the company’s global presence.
Mucocort AB has successfully developed M045A, an innovative mucoadhesive “patch” for the treatment of oral aphthous ulcers. The company has now been granted a patent in Australia for its medical technology innovation, marking a significant milestone in its international expansion.
Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC).
“This approval is a significant step forward in our global growth strategy”, states Jean Lycke, Project Manager at Mucocort AB.
Mucocort AB has received approval from the Swedish Medical Products Agency and the Ethics Review Board to commence a clinical trial of an intraoral patch (M045A) for the treatment of aphthous stomatitis, a condition affecting approximately 2 percent of the population and causing frequent mouth ulcers with significant pain for affected patients.
“We are pleased to soon be ready to welcome our first patient to the trial,” says Jean Lycke, project manager for Mucocort AB.
Swedish MedTech company Mucocort plans to launch a mucosal self-absorbing patch for pain relief in people suffering from aphthous stomatitis (mouth ulcers). The interest in Mucocort patch technology has increased after the approval of a European patent. Further, the Mucocort AB minority stakeholder Aurena Laboratories steps up with additional capital and increases its ownership.
Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers – aphthous stomatitis. The company has now signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort.
Two representatives of the UBI company Mucocort have published an article in the Stockholm Intellectual Property Law Review on one of the most interesting research discoveries the recent decades – the discovery of CRISPR/Cas9, which can result in a Nobel Prize.